EP0696199A1 - Acide boronique a substitution amidino et guanidino en tant qu'inhibiteur d'enzymes de type trypsine - Google Patents

Acide boronique a substitution amidino et guanidino en tant qu'inhibiteur d'enzymes de type trypsine

Info

Publication number
EP0696199A1
EP0696199A1 EP94914776A EP94914776A EP0696199A1 EP 0696199 A1 EP0696199 A1 EP 0696199A1 EP 94914776 A EP94914776 A EP 94914776A EP 94914776 A EP94914776 A EP 94914776A EP 0696199 A1 EP0696199 A1 EP 0696199A1
Authority
EP
European Patent Office
Prior art keywords
pro
phe
borophe
alkyl
nhc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP94914776A
Other languages
German (de)
English (en)
Other versions
EP0696199A4 (fr
Inventor
John Matthew Fevig
Charles Adrian Kettner
Sheng-Lian O. Lee
David John Carini
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Pharma Co
Original Assignee
DuPont Merck Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DuPont Merck Pharmaceutical Co filed Critical DuPont Merck Pharmaceutical Co
Publication of EP0696199A1 publication Critical patent/EP0696199A1/fr
Publication of EP0696199A4 publication Critical patent/EP0696199A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the present invention relates generally to Ot— aminoboronic acids and corresponding peptide analogs in which the alpha substituent is either an aromatic guanidino, isothiouronium, amidino group, halogen, cyano group or an aliphatic amidino, isothiouronium, or formamidino group.
  • ⁇ -aminoboronic acids The chemistry of ⁇ -aminoboronic acids was further expanded to the synthesis of peptide analogs containing boronic acid with positive charged sidechains, boroLysine, boroArginine, boroOrnithine, and isothiouronium analogs (EPA 0 293 881, 12/7/88) .
  • This series of compounds have provided highly effective inhibitors of thrombin and other trypsin-like enzymes.
  • the boroArginine analogs specifically designed as thrombin inhibitors are highly effective in the inhibition of blood coagulation both in vitro and in vivo .
  • this group of compounds is extended to aliphatic amidino and formamidino, to aromatic amidino and guanidino, and to cyano and halogen substituted aromatic boronic acid analogs.
  • This specialized group of compounds where Z is -B(R 2 ) (R 3 ) fall within the scope of our present application.
  • R 1 is a) Cl-C12-alkyl substituted with -CN, -C(NH)NHR 6 ,
  • X is a) halogen (F, Cl, Br, I) b) -CN, c) -N02, d) -CF3, e) -NH2 f) -NHC(NH)H, g) -NHC (NH)NHOH, h) -NHC(NH)NHCN, i) -NHC(NH)NHR 6 , j) -NHC (NH)NHCOR 6 , k) -C(NH)NHR 6 '
  • R 2 is a) H, b) Cl-C4-alkyl, c) aryl, wherein aryl is phenyl or napthyl optionally substituted with one or two substituents selected from the group consisting of halo (F, Cl, Br, I), Cl-C4-alkyl, Cl-C4-alkoxy, -NO2, -CF3, -S(0) r -Cl-C4-alkyl, -OH, -NH2, -NH(Cl-C4-alkyl) , -N(Cl-C4-alkyl)2, -CO ⁇ R 4 , or d) -Cl-C4-alkylaryl, where aryl is defined above
  • A is an amino acid residue or a peptide comprised of 2- 20 amino acid residues;
  • Y 1 and Y 2 are a) -OH, b) -F, c) Cl-C8-alkoxy, or when taken together Y ⁇ and Y 2 form a d) cyclic boron ester where said chain or ring contains from 2 to 20 carbon atoms and, optionally, 1-3 heteroatoms which can be N, S, or 0, n is 0 or 1; p is 0 to 3; q is 0 to 4; r is 0 to 2; and pharmaceutically acceptable salts thereof, with the proviso that when R ⁇ is aliphatic, an R 6 substituent on -NHC(NH)NHR 6 cannot be H.
  • Y 1 and Y 2 are a) -OH, when taken together Y ⁇ and Y 2 form a b) cyclic boron pinacol ester, or c) cyclic boron pinanediol ester;
  • R 1 is a) -(CH 2 )3NHC(NH)H, b) -(CH2)4C(NH)NH2, c)
  • R 2 is H
  • A is Pro or (D)Phe-Pro
  • R 3 is a) H, b) Boc, c) Z, or d) Ac, or e) hydrocinnamoyl f) C1-C10 alkyl sulfonyl g) C1-C15 alkylaryl sulfonyl
  • compositions comprising one or more of the foregoing compounds and methods of using such compositions in the treatment of aberrant proteolysis such as thrombosis in mammals or as reagents used as anticoagulants in the processing of blood to plasma for diagnostic and other commercial purposes .
  • Trp L-tryptophan
  • boro indicates amino acid residues where the carboxyl is replaced by a boronic acid or a boronic acid ester.
  • R 1 is isopropyl and Y 1 and Y 2 are OH
  • the C-terminal residue is abbreviated "boroVal-OH” where "-OH” indicates the boronic acid is in the form of the free acid.
  • the pinanediol boronic acid ester and the pinacol boronic acid ester are abbreviated "-CioHig" and "-C6H 2", respectively. Examples of other useful diols for esterification with the boronic acids are
  • CH NH
  • the formamidino analog of -boroOrn-OH ⁇ -NH- CH[ (CH2)3-NH-CH(NH)H]B(OH)2 ⁇ is -boroOrn (CH NH) -OH.
  • Analogs containing sidechain substituents are described by indicating the substituent in parenthesis following the name of the parent residue.
  • the analog of boroPhenylalanine containing a meta cyano group is -boroPhe (mCN) -.
  • BSA benzene sulfonic acid
  • THF tetrahydrofuran
  • Boc- t-butoxycarbonyl-
  • Ac- acetyl
  • pNA p-nitro-aniline
  • LRMS(NH3-CI) and HRMS(NH3-CI) are low and high resolution mass spectrometry, respectively, using NH3 as an ion source.
  • the compounds of the present invention contain one or more chiral centers and that these stereoisomers may possess distinct physical and biological properties.
  • the present invention comprises all of the stereoisomers or mixtures thereof.
  • the pure enantiomers or diasteromers may be prepared using starting materials with the appropriate stereochemistry, or may be separated from mixtures of undesired stereoisomers by standard techniques, including chiral chromatography and recrystalization of diastereomeric salts .
  • NH2-blocking group refers to various acyl, thioacyl, alkyl, sulfonyl, phosphoryl, and phosphinyl groups comprised of 1 to 20 carbon atoms. Substitutes on these groups maybe either alkyl, aryl, alkylaryl which may contain the heteroatoms, 0, S, and N as a substituent or as inchain component .
  • a number of NH2 ⁇ blocking groups are recognized by those skilled in the art of organic synthesis. By definition, an NH2- blocking group may be removable or may remain permanently bound to the NH 2 .
  • Suitable groups include formyl, acetyl, benzoyl, trifluoroacetyl, and methoxysuccinyl; alkyl and alkylaryl sulfonyl groups, such as n-propylsulfonyl, phenylmethyl and benzylsulfonyl; aromatic urethane protecting groups, such as, benzyloxycarbonyl; and aliphatic urethane protecting groups, such as t-butoxycarbonyl or adamantyloxycarbonyl .
  • Gross and Meinhoffer, eds . The Peptides, Vol 3; 3-88 (1981), Academic Press, New York, and Greene and Wuts Protective Groups in Organic
  • amino acid residues refers to natural or unnatural amino acids of either D- or L- configuratio . Natural amino acids residues are Ala, Arg, Asn, Asp, Aze, Cys, Gin, Glu, Gly, His, He, Irg
  • amino acids residues also refers to various amino acids where sidechain functional groups are coupled with appropriate protecting groups known to those skilled in the art.
  • the Peptides Vol 3, 3-88 (1981) discloses numerous suitable protecting groups and is incorporated herein by reference for that purpose.
  • Novel peptide boronic acids containing aliphatic sidechains were prepared by the series of reactions outlined in Scheme I.
  • An example of this product is J where the above intermediate is coupled to Ac- (D)Phe-Pro-OH. J was converted to the corresponding alkyl cyanide 2.
  • the formamidino substituted boronic acid, ⁇ was prepared by the synthesis of the corresponding alkyl amine such as Ac- (D)Phe-Pro-boroOrn-CirjHi ⁇ , Scheme 2 This in turn was prepared by treating 1 with sodium azide followed by hydrogenation (Kettner et al., 1990) The amine, __., was treated with ethyl formimidate to yield the formamidino compound, ___ .
  • N-substituted isothiouronium derivatives and N- substituted guanidines are readily prepared as shown in Scheme 2a.
  • Treatment of bromide -I with a thiourea produces directly the isothiouronium 1.
  • Alternatively 1 can be converted to the amine __. as shown in Scheme 2.
  • the amine then is heated with a formamidinesulfonic acid in the presence of 4-DMAP to afford the guanidine 22.
  • the required formamidinesulfonic acids can be prepared by oxidation of the corresponding thioureas, see: Walter and Randau, Liebigs Ann . Chem . 722, 98 (1969) .
  • the substituted boronic acid, ___ is prepared by treating 4. with dimethyl cyanodithioiminocarbonate or diphenyl cyanodicarbonimiate to yield the S-methyl isourea (£) or O-phenyl isourea, respectively, using a procedure similar to that reported by Barpill et al. J. Hereocycli c Che . 25, 1698 (1988), Scheme 3. This intermediate is treated with ammonia in either THF or alcohol to yield the desired product .
  • Aromatic guanidino inhibitors 2 ⁇ were prepared from precursor R-boroPhe-C ⁇ rjHi6.
  • the amine is converted to the guanidine by reaction with aminoiminomethane sulfonic acid [Mosher et al. Tetrahedral Lett . 29 3183 (1988)] or cyanamide (Kettner et al. 1990) .
  • the intermediate, Ac- (D)Phe-Pro-NH-CH[ (CH2) 4Br]B ⁇ 2" ioHi ⁇ . was prepared using the mixed anhydride procedure.
  • Ac- (D)Phe-Pro-OH (3.04 g, 10 mmol) was dissolved in 50 mL of THF and N-methylmorpholine (1.1 mL, 10 mmol) was added.
  • the solution was cooled to -20°C using a CCI 4 dry ice bath and isobutyl chloroformate (1.30 mL, 10 mmol) was added.
  • nitrile (Example 1, 0.40 g, 0.70 mmol) was dissolved in 50 mL of a cold solution of saturated HCI in methanol and the solution was ' stirred overnight at 4°C. The solution was then concentrated under reduced pressure. The residue was dissolved in anhydrous methanol (50 mL) , gaseous NH 3 was bubbled through the solution for 1 h, and the solution was heated at 50 °C for 3 h. Solvent was evaporated, the residue was suspended in minimum volume of methanol, and 0.11 g of benzenesulfonic acid (1 eq) was added. Methanol was evaporated and the residue was triturated with hexane to yield the desired product as a pale yellow powder (0.52 g, 99 % yield) .
  • pinanediol protecting group on the boronic acid portion of Ac- (D)Phe-Pro-NHCH [ (CH2) 3-NHC (NH)H] -BO2- C ⁇ oHi6»HCl was removed by transesterification using the procedure we have described previously in U.S.Application 08/010731.
  • the pinanediol ester (0.30 g, 0.51 mmol) and phenyl boronic acid (0.31 g, 2.6 mmol) were suspended in 10 mL of a 1: 1 mixture of ether and water and was allowed to stir for 2.5 h at room temperature. The phases were separated and the aqueous phase was extensively washed with ether.
  • Boc-Pro-boroOrn-C ⁇ oHi6*BSA was also prepared by the procedure described previously (Kettner et al . 1990) .
  • This peptide (3.0 g, 6.5 mmol) was dissolved in 25 mL of absolute ethanol, 4-N,N-dimethylaminopyridine (1.6 g, 12.9 mmol) and ethyl formimidate»HCl (1.4 g, 12.9 mmol) were added.
  • the solution was heated on a 85 °C oil bath for 1 h. Solvent was evaporated and the residue was dissolved in methanol and was chromatogramed on a 2.5 X 100 cm column of LH20 in methanol to yield 1.3 g of the desired product.
  • NHC(NH)H]B02-CioHi6* 0.40 BSA, 0.60 HCI (Example 6, 0.16 g, 0.22 mmol) and phenyl boronic acid (0.13g, 1.1 mmol) were placed in mixture of 5 mL of ether and 5 mL of water and was allowed to stir for 4 h at room temperature. The phases were separated and the organic phase was washed with 5 mL of water. The combined aqueous phases were extensively washed with ether. The aqueous phase was evaporated and the residue triturated with ether to yield the desired product as a white solid, 0.10 g. LRMS (NH3-CI) m/e calcd.
  • the first intermediate, Cl-CH [CH 2 - (m- cyanophenyl) ]B0 2 -C ⁇ oHi6 was prepared from m-cyanobenzyl bromide and dichloromethyl boronate pinanediol.
  • Zinc dust (1.0 g) in 1 mL of THF was cooled to 0-5°C and a solution of m-cyanobenzyl bromide (1.37 g, 7.0 mmol) in 7 mL of THF was added dropwise (5 sec/drop) .
  • the reaction mixture was allowed to stir at 5°C for 2 h.
  • Example 14 Cl-CH [CH 2 - (m-bromo-phenyl) ]B0 2 -C ⁇ oHi 6 was prepared making the anion of -bromobenzyl bromide and coupling it to dichloromethyl boronic acid pinanediol. This intermediate and the corresponding amine were prepared using the procedure described for Example 10. The amine was coupled to Ac- (D) Phe-Pro-OH using the method described in Example 11.
  • ClCH[CH2C6H - -CN]B ⁇ 2C ⁇ oHi6 was prepared by making the anion of p-cyanobenzyl bromide and coupling it to dichloromethyl boronate pinanediol. This intermediate and the corresponding amine were prepared using the procedure described for Example 10. NH2CH[CH2C6H4- - CN]B ⁇ 2C ⁇ oHi6 (Example 78) was coupled to Ac- (D)Phe-Pro- OH using the method described in Example 11.
  • Boc- (D)Phe-Pro-boroPhe ( CN) -C10H16 was prepared by reacting Boc- (P)Phe-Pro-OH (0.43 g, 1.2 mmol), H- boroPhe(mCN)-C ⁇ oHi6*HCl (0.42 g, 1.2 mmol), N- methylrnorpholine (0.26 mL, 2.4 mmol), hydroxybenzotriazole»H2 ⁇ (0.36 g, 2.4 mmol), and dicyclohexylcarbodiimide (0.25 g, 1.2 mmol) in 20 mL of dichloromethane overnight at room temperature . The reaction mixture was filtered and the filtrate was chromatogramed on a 2.5 X 100 cm column of Sephedex LH- 20 in methanol to yield 0.36 g of the desired product.
  • Boc- (P)Phe-Pro-boroPhe (mCN)-C ⁇ oHi6 (0.21 g) was allowed to react with 2 mL of 4 N HCI dioxane for 2 h at room temperature. Solvent was removed by evaporation and the residue was triturated with ether to yield 0.11 g of the desired product as a white solid.
  • H-(D)Phe-Pro-boroPhe(mCN)-OH-HCl (0.20 g, 0.42 mmol)
  • 37% aqueous formaldehyde (0.34 mL, 4.2 mmol) were " dissolved in 2 mL of acetonitrile.
  • Sodium cyanoborohydride (0.080 g, 1.3 mmol) was added and after 5 min glacial acetic acid (20 ⁇ L) were added. The reaction pH was ⁇ 7. After 5 h, additional acetic acid (20 ⁇ L) were added and the mixture was stirred for 1 h.
  • reaction mixture was poured into 20 mL of ethyl acetate and the organic phase was washed with 10 mL of saturated aqueous sodium chloride and dried over anhydrous sodium sulfate. Evaporation of solvent yielded 0.16 g of an oil which was triturated with ether to give a white solid.
  • Table 1 can be prepared by the schemes and procedures described above using the appropriate starting materials. Table 1 ,
  • N-Acyl and N-peptide boronic acids which are described in the present invention represent a novel class of potent, reversible inhibitors of trypsin-like enzymes.
  • Trypsin-like enzymes are a group of proteases which hydrolyzed peptide bonds at basic residues liberating either a C-terminal arginyl or lysyl residue.
  • enzymes of the blood coagulation and fibrinolytic system required for hemostasis They are Factors II, X, VII, IX, XII, kallikrein, tissue plasminogen activators, urokinase-like plasminogen activator, and plasmin.
  • Enzymes of the complement system, acrosin (required for fertilization), pancreatic trypsin are also in this group. Elevated levels of proteolysis by these proteases can result in disease states. For example, consumptive coagulopathy, a condition marked by a decrease in the blood levels of enzymes of both the coagulation system, the fibrinolytic system and accompanying protease inhibitors is often fatal . Intervention by a synthetic inhibitor would clearly be valuable. More specifically, proteolysis by thrombin is required for blood clotting. Inhibition of thrombin results in an effective inhibitor of blood clotting.
  • the compounds of this invention When used in the processing of blood products, the compounds of this invention may be mixed with whole blood without the need for any additional anticoagulants.
  • the compounds of this invention serve to inhibit blood coagulation thereby facilitating the processing of whole blood into desired cellular components or plasma proteins.
  • the compounds Once the processing is complete, the compounds may be removed, if so desired, by membrane ultrafiltration, dialysis, or diafiltration to afford the desired product.
  • the low molecular weight of these compounds relative to conventional anticoagulants like heparin allow them to be separated from desired products more easily.
  • Compounds of the present invention are expected to be effective in the control of aberrant proteolysis and a number of accompanying disease states such as inflammation, pancretitis, and heritary angioedema.
  • the in vitro effectiveness of compounds of the present invention as inhibitors of the blood coagulation protease thrombin was determined under two different conditions: (1) measurements in buffered solutions using a synthetic substrate; (2) measurement in plasma where the rate of blood clotting is determined.
  • the chromogenic substrate S2238 H- (D)Phe-Pip- Arg-PNA, where PIP refers to pipecolic acid; Helena Laboratories, Beaumont, TX
  • Ki values of Ki were determined by allowing thrombin (0.19 nM) to react with substrate (0.20 M) in the presence of inhibitor. Reactions were allowed to go for 30 minutes and the velocities (rate of absorbance change vs time) were measured in the time frame of 25-30 minutes. The following relationship was used to calculate Ki values.
  • v 0 is the velocity of the control in the absence of inhibitor
  • v s is the velocity in the presence of inhibitor
  • I is the concentration of inhibitor
  • Ki is the dissociation constant of enzyme: inhibitor complex
  • S is the concentration of substrate
  • K m is the Michaelis constant
  • Plasma was prepared by diluting blood 1:10 with 3.2% aqueous citric acid and centrifuging. Buffer consisted of 0.10 M Tris, pH 7.4, containing 0.9% sodium chloride, and 2.5 mg/mL bovine serum albumin. Bovine thrombin was obtained from
  • Plasma 200 ⁇ L
  • buffer 50 ⁇ L
  • thrombin 50 ⁇ L
  • clotting times Controls were run under identical conditions except in the absence of inhibitor.
  • the final concentration of thrombin was 4 NIH units/mL.
  • Ki values were measure at 25 °C at pH 7.5.
  • IC50 level of inhibitor required to prolong clotting to the time observed for 2 NIH units/mL thrombin in the absence of inhibitor
  • IC50 level of inhibitor required to prolong clotting to the time observed for 2 NIH units/mL thrombin in the absence of inhibitor
  • Examples 3, 7, 9, 11, and 12 increased thrombin clotting times 2-fold at 0.25, ⁇ 0.075, 0.10, 0.60, and 0.85 ⁇ M, respectively.
  • the effectiveness of compounds of the present invention as anticoagulants in vivo was demonstrated by the prolongation of the activated partial thromboplastin time of samples of blood taken from conscious dogs or anesthetized rats after either oral or intravenous administration at doses of the compounds from 0.5 to 10 mg/kg.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Nouvel acide α-aminoboronique et analogues peptidiques correspondants de la formule (I).
EP94914776A 1993-04-27 1994-04-21 Acide boronique a substitution amidino et guanidino en tant qu'inhibiteur d'enzymes de type trypsine Withdrawn EP0696199A4 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US5283593A 1993-04-27 1993-04-27
US52835 1993-04-27
US20405594A 1994-03-02 1994-03-02
US204055 1994-03-02
PCT/US1994/004058 WO1994025049A1 (fr) 1993-04-27 1994-04-21 Acide boronique a substitution amidino et guanidino en tant qu'inhibiteur d'enzymes de type trypsine

Publications (2)

Publication Number Publication Date
EP0696199A1 true EP0696199A1 (fr) 1996-02-14
EP0696199A4 EP0696199A4 (fr) 1997-06-25

Family

ID=26731141

Family Applications (1)

Application Number Title Priority Date Filing Date
EP94914776A Withdrawn EP0696199A4 (fr) 1993-04-27 1994-04-21 Acide boronique a substitution amidino et guanidino en tant qu'inhibiteur d'enzymes de type trypsine

Country Status (7)

Country Link
EP (1) EP0696199A4 (fr)
JP (1) JPH08509723A (fr)
AU (1) AU6703894A (fr)
CA (1) CA2161216A1 (fr)
IL (1) IL109319A0 (fr)
TW (1) TW286318B (fr)
WO (1) WO1994025049A1 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL111175A0 (en) * 1993-10-07 1994-12-29 Du Pont Merck Pharma Electrophilic peptide analogs as inhibitors of trypsin-like serine proteases and pharmaceutical compositions containing them
US5561146A (en) * 1994-06-10 1996-10-01 Bristol-Myers Squibb Company Modified guanidino and amidino thrombin inhibitors
FR2721611B1 (fr) * 1994-06-22 1996-09-27 Adir Nouveaux dérivés peptidiques de l'acide boronique, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent .
NZ312791A (en) 1995-07-26 1999-07-29 Mitsubishi Chem Corp Penicillaminamide derivatives
FR2739858B1 (fr) * 1995-10-11 1997-11-14 Synthelabo Derives de n-sulfonyl- et n-sulfamoylpeptidylprolinamide, leur preparation et leur application en therapeutique
US6649593B1 (en) 1999-10-13 2003-11-18 Tularik Inc. Modulators of SREBP processing
US6933290B2 (en) 2001-05-30 2005-08-23 Novartis Ag 2-{N-(2-amino-3-(heteroaryl or aryl)propionyl)-aminoacyl}-amino}-alkylboronic acid derivatives
US7112572B2 (en) 2002-09-09 2006-09-26 Trigen Limited Multivalent metal salts of boronic acids
AU2003263343A1 (en) 2002-09-09 2004-03-29 Trigen Limited Boronic acid salts ant their use in the treatment of thromobis
US7576206B2 (en) 2003-08-14 2009-08-18 Cephalon, Inc. Proteasome inhibitors and methods of using the same
US7223745B2 (en) 2003-08-14 2007-05-29 Cephalon, Inc. Proteasome inhibitors and methods of using the same
US7468383B2 (en) 2005-02-11 2008-12-23 Cephalon, Inc. Proteasome inhibitors and methods of using the same
RU2354647C2 (ru) * 2007-06-28 2009-05-10 Общество С Ограниченной Ответственностью "Бионика" Новые соединения, обладающие функцией ингибиторов тромбина, и фармацевтические композиции на их основе
RU2353619C2 (ru) * 2007-06-28 2009-04-27 Общество С Ограниченной Ответственностью "Бионика" Новые соединения, обладающие функцией антикоагулянтов, фармацевтические композиции на их основе для лечения тромботических состояний и плазмозамещающий раствор для коррекции гиперкоагуляционных нарушений при гемодилюции
WO2011087822A1 (fr) 2009-12-22 2011-07-21 Cephalon, Inc. Inhibiteurs du protéasome et leurs procédés de préparation, d'épuration et d'utilisation
EA201990069A1 (ru) 2016-06-21 2019-06-28 ОРИОН ОФТАЛМОЛОДЖИ ЭлЭлСи Производные гетероциклического пролинамида
JP7164521B2 (ja) 2016-06-21 2022-11-01 オリオン・オフサルモロジー・エルエルシー 炭素環式プロリンアミド誘導体

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992007869A1 (fr) * 1990-11-06 1992-05-14 Thrombosis Research Institute Inhibiteurs et substrats de thrombine
WO1995009634A1 (fr) * 1993-10-07 1995-04-13 The Du Pont Merck Pharmaceutical Company Analogues peptidiques electrophiles servant d'inhibiteurs a des enzymes apparentees a la trypsine

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4499082A (en) * 1983-12-05 1985-02-12 E. I. Du Pont De Nemours And Company α-Aminoboronic acid peptides
US4537773A (en) * 1983-12-05 1985-08-27 E. I. Du Pont De Nemours And Company α-Aminoboronic acid derivatives

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992007869A1 (fr) * 1990-11-06 1992-05-14 Thrombosis Research Institute Inhibiteurs et substrats de thrombine
WO1995009634A1 (fr) * 1993-10-07 1995-04-13 The Du Pont Merck Pharmaceutical Company Analogues peptidiques electrophiles servant d'inhibiteurs a des enzymes apparentees a la trypsine

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
J. AM. CHEM. SOC., vol. 103, 1981, pages 5241-5242, XP002019969 MATTESON, D.S. & SADHU, K.M.: "(R)-1-acetamido-2-phenylethaneboronic acid. ..." *
PEPT.: CHEM. BIOL., PROC. AM. PEPT. SYMP. 12TH, 1992, pages 824-825, XP000609384 CLAESON, G. ET AL.: "Novel peptide mimetics as highly efficient inhibitors of thrombin based on D-Phe-Pro-Arg sequences" *
See also references of WO9425049A1 *
TETRAHEDRON LETTERS, vol. 33, no. 29, 1992, pages 4209-4212, XP000609104 ELGENDY, S. ET AL.: "New peptide boronic acid inhibitors of thrombin" *

Also Published As

Publication number Publication date
IL109319A0 (en) 1994-07-31
WO1994025049A1 (fr) 1994-11-10
AU6703894A (en) 1994-11-21
JPH08509723A (ja) 1996-10-15
TW286318B (fr) 1996-09-21
CA2161216A1 (fr) 1994-11-10
EP0696199A4 (fr) 1997-06-25

Similar Documents

Publication Publication Date Title
CA2200192C (fr) Inhibiteurs amidino et guanidino substitues d'enzymes semblables a la trypsine
EP0293881B1 (fr) Inhibiteurs peptides de l'acide boronique de proteases de type trypsine
EP0696199A1 (fr) Acide boronique a substitution amidino et guanidino en tant qu'inhibiteur d'enzymes de type trypsine
US5462928A (en) Inhibitors of dipeptidyl-aminopeptidase type IV
US7230074B2 (en) Inhibitors of dipeptidyl-aminopeptidase type IV
US5242904A (en) Peptide boronic acid inhibitors of trypsin-like proteases
US5250720A (en) Intermediates for preparing peptide boronic acid inhibitors of trypsin-like proteases
EP1050540B1 (fr) Inhibiteurs de dipeptidyl-aminopeptidase de type IV
EP0145441B1 (fr) Peptides d'acides alpha-aminoboroniques
WO1994021668A1 (fr) Elimination des groupes de protection presents dans l'acide boronique par transesterification
WO1991016339A1 (fr) Inhibiteurs de dipeptidyl-aminopeptidase de type iv
WO1995011689A1 (fr) Utilisation d'inhibiteurs de la dipeptidylaminopeptidase pour bloquer l'entree du vih dans des cellules
NZ250957A (en) Peptide derivatives containing boron; medicaments
US5639739A (en) Imidazole containing aminoboronic acids
WO1995009859A1 (fr) Inhibiteurs boropeptidiques de la thrombine contenant un noyau de pyrrolidine substitue
US5462964A (en) Dipeptide boronic acid inhibitors of trypsin-like enzymes
US6127340A (en) Serine protease inhibitors
US5731439A (en) Piperidine containing aminobornic acids
CA1333208C (fr) Peptides contenant de l'acide boronique inhibant les proteases apparentees a la trypsine
RU1807988C (ru) Способ получени производных борсодержащих пептидов
JP2002519430A (ja) ヒトアンギオテンシン変換酵素のｎ−末端部位選択的阻害薬

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19951017

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

RHK1 Main classification (correction)

Ipc: C07K 5/06

A4 Supplementary search report drawn up and despatched

Effective date: 19970509

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: DUPONT PHARMACEUTICALS COMPANY

RAP3 Party data changed (applicant data changed or rights of an application transferred)

Owner name: DUPONT PHARMACEUTICALS COMPANY

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Withdrawal date: 20001121